Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Study of Ponatinib in Advanced Lung and Head and Neck Cancers With FGFR Kinase Alterations

NCT01761747 is registered in ClinicalTrials.gov with Dana-Farber Cancer Institute as lead sponsor.

NCT NCT01761747
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01761747 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Study of Ponatinib in Advanced Lung and Head and Neck Cancers With FGFR Kinase Alterations
Lead sponsor
Dana-Farber Cancer Institute
Phase
Phase 2/3
Overall status
Terminated
Start date
January 31, 2013
Completion date
June 30, 2014
Enrollment
3 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

non-small cell lung cancer, head and neck cancer